Navigation Links
Akron researcher awarded NIH grant for advancing 3-D tumor models for anticancer drug testing
Date:10/31/2013

The National Institutes of Health is supporting the work of a University of Akron researcher who may hold the key to improving the effectiveness of cancer treatments. The agency has awarded UA's Hossein Tavana a two-year, $511,000 grant to fund his ongoing efforts to improve the testing and effectiveness of anticancer drugs.

Tavana, an assistant professor of biomedical engineering in the College of Engineering, has developed a method to generate 3-D cultures of cancer cells (spheroids) that better model tumors in the body. These improved models have the potential to dramatically improve the screening and discovery of effective chemotherapeutics, Tavana says.

In support of this novel and promising technology, the NIH awarded Tavana its R21 grant, which is defined by the NIH as a developmental research grant intended to support "exploratory, novel studies that break new ground or extend previous discoveries toward new directions or applications."

Drug testing on 2-D cultures of cancer cells, in which thin layers of cells are treated on a flat dish, does not adequately predict how the drugs will behave in the 3-D environment of the body, Tavana says.

Three-dimensional cultures, on the other hand, in which cancer cells aggregate into spherical clusters, better mimic tumors, allowing for more efficient and cost-effective drug screening and discovery, he adds.

This in turn allows researchers to determine which drugs will best treat particular forms of cancer, eliminating the need to treat patients with a battery of drugs in the hope of finding something that works, Tavana explains.

"Rather than throwing a bunch of different drugs into a patient's body, we can say, 'This particular patient, based on this test, will most likely benefit from this chemo drug.'"

Whereas other labs are generating 3-D cancer cell spheroids, or aggregates, one at a time, Hossein's unique method allows him to generate 384 spheroids "robotically and in a single step," drastically expediting drug testing.

The robot, equipped with rows of pipettes, dispenses cancer cells into 384 small wells, or miniature test tubes, each of which contains a liquid that provides nutrients to the immersed cells, allowing them to aggregate as they would in the body, resulting in 384 physiologic tumor models.

Tavana and his research team are currently testing cell lines cells that have been made immortal so they can be reused over and over of triple negative breast cancer cells and skin cancer. Next year they plan to use primary, patient-derived cells, which will allow them to test drugs under more realistic conditions.


'/>"/>

Contact: Denise Henry
henryd@uakron.edu
330-972-6477
University of Akron
Source:Eurekalert  

Related medicine news :

1. Akron General President & CEO deemed 2013 Wellness Warrior
2. Akron General Health System, Kent State University Form Health and Wellness Research Collaborative
3. CottageCare® Akron Now Offers Patio Cleaning
4. Akron researchers devise Rx for ailing wellness programs
5. UTSA researchers develop prototype football kicking simulator
6. CWRU researchers aim nanotechnology at micrometastases
7. Risk of osteoporosis drugs side effects not significant, Loyola researchers find
8. New look at old test may provide earlier detection of meningitis, MU researchers find
9. MUHC researchers identify biomarkers that could leadto early diagnosis of colorectal cancer
10. Unpublished trial data violates an ethical obligation to study participants, say researchers
11. Einstein researchers lead panels at NIH Aging and Chronic Disease Symposium on Geroscience
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Akron researcher awarded NIH grant for advancing 3-D tumor models for anticancer drug testing
(Date:7/26/2017)... ... ... Six greater Bay Area roller derby leagues are partnering with Brown Paper Tickets and the ... of blood drives in California, beginning July 29. Make ‘Em Bleed roller derby blood drives ... to have helped to save up to 2700 lives. , “The Make ‘Em Bleed blood ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... (ISPE) will host its 2017 Process Validation and Process Validation Statistics ... comprehensive solutions to process validation lifecycle challenges faced by process validation professionals ...
(Date:7/26/2017)... ... July 26, 2017 , ... A global ... in Jupiter. The state of the art center will provide advanced surgical ... a goal of providing heart patients longer lives. , North American Veterinary Heart ...
(Date:7/26/2017)... , ... July 26, 2017 , ... ... innovative specialty pharmacies, has released an updated version of the HCV Treatment Path ... for treating chronic hepatitis C virus (HCV) infection. All of the latest HCV ...
(Date:7/25/2017)... (PRWEB) , ... July 25, 2017 , ... ... to announce the launch of their partnership to provide the Pharmacist eCare ... first pharmacy-focused platform in the country with the ability to develop the Pharmacist ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... EDMONTON, Alberta , July 21, 2017 ... the University of Alberta in Edmonton, ... Nature,s partner journal, Schizophrenia 1 , demonstrating that ... of schizophrenia with 74% accuracy. This retrospective analysis ... specific symptoms in schizophrenia patients with significant correlation, ...
(Date:7/20/2017)... PAUL, Minn. , July 20, 2017  Prime Therapeutics ... Jonathan Gavras , M.D., following today,s Institute for Clinical ... report on the effectiveness and value of abuse-deterrent ... manager on the policy roundtable at the meeting. ... is not a material cost benefit to the use of ...
(Date:7/14/2017)... , July 14, 2017 Endo International plc (NASDAQ: ... Tuesday, August 8, 2017.  Members of its senior management team will ... open at 8:30 a.m. ET. The dial-in number ... 497-0462, International (678) 509-7598, and the passcode is 45397076. Please dial ... A replay of the call will ...
Breaking Medicine Technology: